Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. (PTGX) Stock Overview

Explore Protagonist Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PTGX●NASDAQ
HealthcareBiotechnology
$154.32
$3.63(2.41%)
U.S. Market opens in 62h 3m

Protagonist Therapeutics, Inc. (PTGX)

Meyka AI Score

Z

Key Financials

Market Cap9.9B
P/E Ratio125.84
EPS (TTM)$1.03
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 Month$151.83
3 Months$156.59
1 Year Target$136.31

PTGX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Protagonist Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PTGX on the NASDAQ shows an RSI of 62.78, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $136.31 for the NASDAQ listing.

Key metrics behind Protagonist Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 125.84 and a market capitalization of 9.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of PTGX on the NASDAQ.

Price Performance (NASDAQ: PTGX)

1-Day Change
2.46%
5-Day Change
2.77%
1-Month Change
11.63%
3-Month Change
51.35%
6-Month Change
86.56%
Year-to-Date (YTD) Change
76.78%
1-Year Change
175.51%
3-Year Change
690.56%
5-Year Change
211.35%
All-Time (Max) Change
1219.62%

Contact Information

https://www.protagonist-inc.com
510 474 0170
7707 Gateway Boulevard, Newark, CA, 94560

Company Facts

1,320 Employees
IPO DateAug 11, 2016
CountryUS
Actively Trading

Frequently Asked Questions